Ian D. Krantz,Livija Medne,Jamila M. Weatherly,K. Taylor Wild,Sawona Biswas,Batsal Devkota,Tiffiney Hartman,Luca Brunelli,Kristen P. Fishler,Omar Abdul-Rahman,Joshua C. Euteneuer,Denise Hoover,David Dimmock,John Cleary,Lauge Farnaes,Jason Knight,Adam J. Schwarz,Ofelia M. Vargas-Shiraishi,Kristin Wigby,Neda Zadeh,Marwan Shinawi,Jennifer A. Wambach,Dustin Baldridge,F. Sessions Cole,Daniel J. Wegner,Nora Urraca,Shannon Holtrop,Roya Mostafavi,Henry J. Mroczkowski,Eniko K. Pivnick,Jewell C. Ward,Ajay Talati,Chester W. Brown,John W. Belmont,Julia L. Ortega,Keisha D. Robinson,W. Tyler Brocklehurst,Denise L. Perry,Subramanian S. Ajay,R. Tanner Hagelstrom,Maren Bennett,Vani Rajan,Ryan J. Taft,

Abstract:ImportanceWhole-genome sequencing (WGS) shows promise as a first-line genetic test for acutely ill infants, but widespread adoption and implementation requires evidence of an effect on clinical management.ObjectiveTo determine the effect of WGS on clinical management in a racially and ethnically diverse and geographically distributed population of acutely ill infants in the US.Design, Setting, and ParticipantsThis randomized, time-delayed clinical trial enrolled participants from September 11, 2017, to April 30, 2019, with an observation period extending to July 2, 2019. The study was conducted at 5 US academic medical centers and affiliated children's hospitals. Participants included infants aged between 0 and 120 days who were admitted to an intensive care unit with a suspected genetic disease. Data were analyzed from January 14 to August 20, 2020.InterventionsPatients were randomized to receive clinical WGS results 15 days (early) or 60 days (delayed) after enrollment, with the observation period extending to 90 days. Usual care was continued throughout the study.Main Outcomes and MeasuresThe main outcome was the difference in the proportion of infants in the early and delayed groups who received a change of management (COM) 60 days after enrollment. Additional outcome measures included WGS diagnostic efficacy, within-group COM at 90 days, length of hospital stay, and mortality.ResultsA total of 354 infants were randomized to the early (n = 176) or delayed (n = 178) arms. The mean participant age was 15 days (IQR, 7-32 days); 201 participants (56.8%) were boys; 19 (5.4%) were Asian; 47 (13.3%) were Black; 250 (70.6%) were White; and 38 (10.7%) were of other race. At 60 days, twice as many infants in the early group vs the delayed group received a COM (34 of 161 [21.1%; 95% CI, 15.1%-28.2%] vs 17 of 165 [10.3%; 95% CI, 6.1%-16.0%];P = .009; odds ratio, 2.3; 95% CI, 1.22-4.32) and a molecular diagnosis (55 of 176 [31.0%; 95% CI, 24.5%-38.7%] vs 27 of 178 [15.0%; 95% CI, 10.2%-21.3%];P < .001). At 90 days, the delayed group showed a doubling of COM (to 45 of 161 [28.0%; 95% CI, 21.2%-35.6%]) and diagnostic efficacy (to 56 of 178 [31.0%; 95% CI, 24.7%-38.8%]). The most frequent COMs across the observation window were subspecialty referrals (39 of 354; 11%), surgery or other invasive procedures (17 of 354; 4%), condition-specific medications (9 of 354; 2%), or other supportive alterations in medication (12 of 354; 3%). No differences in length of stay or survival were observed.Conclusions and RelevanceIn this randomized clinical trial, for acutely ill infants in an intensive care unit, introduction of WGS was associated with a significant increase in focused clinical management compared with usual care. Access to first-line WGS may reduce health care disparities by enabling diagnostic equity. These data support WGS adoption and implementation in this population.Trail RegistrationClinicalTrials.gov Identifier:NCT03290469

Clinical genome sequencing in patients with suspected rare genetic disease in Peru

Facing the challenges to shorten the diagnostic odyssey: first Whole Genome Sequencing experience of a Colombian cohort with suspected rare diseases

Diagnostic and Clinical Utility of Whole Genome Sequencing in a Cohort of Undiagnosed Chinese Families with Rare Diseases

Overcoming barriers to equitable genomic healthcare

Implementation of genomic medicine for rare disease in a tertiary healthcare system: Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD)

Evaluating the performance of a clinical genome sequencing program for diagnosis of rare genetic disease, seen through the lens of craniosynostosis

The Peruvian Genome Project: expanding the global pool of genome diversity from South America

Results of the First In Situ Implementation of Comprehensive Genomic Profiling

Genome Sequencing reveals the impact of non-canonical exon inclusions in rare genetic disease

Structural and non-coding variants increase the diagnostic yield of clinical whole genome sequencing for rare diseases

Decoding complex inherited phenotypes in rare disorders: the DECIPHERD initiative for rare undiagnosed diseases in Chile

Integrated multi-omics for rapid rare disease diagnosis on a national scale

Genome Sequencing for Diagnosing Rare Diseases

Hospital-wide access to genomic data advanced pediatric rare disease research and clinical outcomes

A genome sequencing system for universal newborn screening, diagnosis, and precision medicine for severe genetic diseases

Diagnostic yield of exome and genome sequencing after non-diagnostic multi-gene panels in patients with single-system diseases

Expanded Newborn Screening Using Genome Sequencing for Early Actionable Conditions

Evaluating Genome Sequencing Strategies: Trio, Singleton, and Standard Testing in Rare Disease Diagnosis

SeqFirst: Building equity access to a precise genetic diagnosis in critically ill newborns

Effect of Whole-Genome Sequencing on the Clinical Management of Acutely Ill Infants With Suspected Genetic Disease

Patient Experience of Complex Genomic Sequencing Exploring Patient Preference, Barriers, and Enablers for Delivery